Global initiative for chronic obstructive lung disease (GOLD) recommendations: strengths and concerns for future needs

References

• Surani S, Aiyer A, Eikermann S, et al. Adoption and adherence to chronic obstructive pulmonary disease GOLD guidelines in a primary care setting. SAGE Open Med. 2019;7:2050312119842221.
   Web of Science ®Google Scholar
• Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med. 2001 Apr;163(5):1256–1276.
   PubMedGoogle Scholar
• Pauwels R. Global initiative for chronic obstructive lung diseases (GOLD): time to act. Eur Respir J. 2001 Dec;18(6):901–902.
   PubMed Web of Science ®Google Scholar
• Global Strategy for the Diagnosis, Management, and prevention of chronic obstructive pulmonary disease. 2019. [cited 2019 Feb 1] Available from www.goldcopd.org
   Google Scholar
• Fabbri LM, Hurd SS, Committee GS. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J. 2003 Jul;22(1):1–2.
   PubMed Web of Science ®Google Scholar
• www.goldcopd.org, 2022 GOLD Report
   Google Scholar
• Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med.2007 Sep 15;176(6):532–555.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2002 Aug 1;166(3):329–332.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013 Feb 15;187(4):347–365.
   PubMed Web of Science ®Google Scholar
• Global Strategy for Prevention. Diagnosis and management of COPD 2011. 2011.
   Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010 Sep 16;363(12):1128–1138.
   PubMed Web of Science ®Google Scholar
• Heidelbaugh JJ. Elsevier Inc. Chronic obstructive pulmonary disease: a multidisciplinary approach. Elsevier Health Sciences; 2015.
   Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. Wedzicha and Alvar Agusti. 2017;49:1700214. Eur Respir J. 2017 Jun;49(6);(3)
   PubMed Web of Science ®Google Scholar
• Global Strategy For Prevention, Diagnosis and management of COPD: 2022 report. 2022.
   Google Scholar
• Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005 Nov;60(11):925–931.
   PubMed Web of Science ®Google Scholar
• Piquet J, Chavaillon JM, David P, et al. High-risk patients following hospitalisation for an acute exacerbation of COPD. Eur Respir J. 2013 Oct;42(4):946–955.
   PubMed Web of Science ®Google Scholar
• Mannino DM, Doherty DE, Sonia Buist A. Global initiative on obstructive lung disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006 Jan;100(1):115–122.
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004 Mar 4;350(10):1005–1012.
   PubMed Web of Science ®Google Scholar
• Jose Soler-Cataluna J, Alcazar-Navarrete B, Miravitlles M. The concept of control in COPD: a new proposal for optimising therapy. Eur Respir J. 2014 Oct;44(4):1072–1075.
   PubMed Web of Science ®Google Scholar
• Barrecheguren M, Kostikas K, Mezzi K, et al. COPD clinical control as a predictor of future exacerbations: concept validation in the SPARK study population. Thorax. 2020 Apr;75(4):351–353.
   PubMed Web of Science ®Google Scholar
• Soriano JB, Lamprecht B, Ramirez AS, et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respir Med. 2015 Jun;3(6):443–450.
   PubMed Web of Science ®Google Scholar
• Kim J, Yoon HI, Oh YM, et al. Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1819–1827.
   PubMed Web of Science ®Google Scholar
• Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med. 2013 Mar;1(1):43–50.
   PubMed Web of Science ®Google Scholar
• Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014 Dec;44(6):1697–1700.
   PubMed Web of Science ®Google Scholar
• Siddiqui SH, Guasconi A, Vestbo J, et al. Blood Eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015 Aug 15;192(4):523–525.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015 Jun;3(6):435–442.
   PubMed Web of Science ®Google Scholar
• Roche N, Chapman KR, Vogelmeier CF, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. data from the FLAME trial. Am J Respir Crit Care Med. 2017 May 1;195(9):1189–1197.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018 Feb;6(2):117–126.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016 Jun 9;374(23):2222–2234.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018 May 3;378(18):1671–1680.
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018 Mar 17;391(10125):1076–1084.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Thomashow B, Sapir T, et al. Does evaluation and management of COPD follow therapeutic strategy recommendations? Chronic Obstr Pulm Dis. 2021 Apr 27;8(2):230–242.
   PubMed Web of Science ®Google Scholar
• Kohansal R, Martinez-Camblor P, Agusti A, et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med. 2009 Jul 1;180(1):3–10.
   PubMed Web of Science ®Google Scholar
• de Marco R, Accordini S, Cerveri I, et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med. 2007 Jan 1;175(1):32–39.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Han MK, Allinson JP, et al. At the root: defining and halting progression of early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018 Jun 15;197(12):1540–1551.
   PubMed Web of Science ®Google Scholar
• Leung JM, Obeidat M, Sadatsafavi M, et al. Introduction to precision medicine in COPD. Eur Respir J. 2019 Apr;53(4):1802460.
   PubMed Web of Science ®Google Scholar
• Agusti A. The path to personalised medicine in COPD. Thorax. 2014 Sep;69(9):857–864.
   PubMed Web of Science ®Google Scholar
• Burke H, Wilkinson TMA. Unravelling the mechanisms driving multimorbidity in COPD to develop holistic approaches to patient-centred care. Eur Respir Rev. 2021 Jun 30;30(160):210041.
   PubMed Web of Science ®Google Scholar
• Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011 Jan;12(1):56–68.
   PubMed Web of Science ®Google Scholar
• Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008 Oct;32(4):962–969.
   PubMed Web of Science ®Google Scholar
• Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: role of comorbidities. Eur Respir J. 2006 Dec;28(6):1245–1257.
   PubMed Web of Science ®Google Scholar
• Volpato S, Bianchi L, Lauretani F, et al. Role of muscle mass and muscle quality in the association between diabetes and gait speed. Diabetes Care. 2012 Aug;35(8):1672–1679.
   PubMed Web of Science ®Google Scholar
• Park SW, Goodpaster BH, Strotmeyer ES, et al. Accelerated loss of skeletal muscle strength in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes Care. 2007 Jun;30(6):1507–1512.
   PubMed Web of Science ®Google Scholar
• Hillas G, Perlikos F, Tzanakis N. Acute exacerbation of COPD: is it the “stroke of the lungs”? Int J Chron Obstruct Pulmon Dis. 2016;11:1579–1586.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012 Nov;67(11):957–963.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011 Sep 15;184(6):662–671.
   PubMed Web of Science ®Google Scholar
• Waeijen-Smit K, Houben-Wilke S, DiGiandomenico A, et al. Unmet needs in the management of exacerbations of chronic obstructive pulmonary disease. Intern Emerg Med. 2021 Apr;16(3):559–569.
   PubMed Web of Science ®Google Scholar
• Cote CG, Celli BR. BODE index: a new tool to stage and monitor progression of chronic obstructive pulmonary disease. Pneumonol Alergol Pol. 2009;77(3):305–313.
   PubMedGoogle Scholar
• Ong KC, Earnest A, Lu SJ. A multidimensional grading system (BODE index) as predictor of hospitalization for COPD. Chest. 2005 Dec;128(6):3810–3816.
   PubMed Web of Science ®Google Scholar
• Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009 Aug 29;374(9691):704–711.
   PubMed Web of Science ®Google Scholar
• Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med. 2009 Dec 15;180(12):1189–1195.
   PubMed Web of Science ®Google Scholar
• Hillas G, Papaporfyriou A, Dimakou K, et al. Pharmacological treatment of stable COPD: need for a simplified approach. Postgrad Med. 2020 Mar;132(2):126–131.
   PubMed Web of Science ®Google Scholar
• Hillas G, Papaporfyriou A, Dimakou K, et al. Updated simplified approach of pharmacological treatment of stable COPD: do common comorbidities have a role? Postgrad Med. 2021 Nov;133(8):873–874.
   PubMed Web of Science ®Google Scholar